Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00963105 · ClinicalTrials.gov registry record · Phase 2
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
A Phase 2 study of Relapsed or Refractory Chronic Lymphocytic Leukemia, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
- 20
- Study locations
NCT00963105 is a Phase 2 study of Relapsed or Refractory Chronic Lymphocytic Leukemia that has completed, run by Celgene. The registered enrollment target is 104 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT00963105, a Phase 2 study of Relapsed or Refractory Chronic Lymphocytic Leukemia, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and effectiveness of different dose regimens of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Conditions Studied
Interventions
- DRUG lenalidomide
Study Locations (20)
California
- UCSD Moores Cancer Center - La Jolla
- Desert Hematology Oncology Medical Group, Inc. - Rancho Mirage
- Stanford University School of Medicine - Stanford
Illinois
- Northwestern University Medical Center Division of Hematology Oncology - Chicago
- Rush University Medical Center - Chicago
New York
- Roswell Park Cancer Institute - Buffalo
- Long Island Jewish Medical Center CLL Research and Treatment Program - New Hyde Park
Ohio
- Gabrail Cancer Center Research - Canton
- Cleveland Clinic Foundation - Cleveland
Other
- CHU Sud - Amiens
- Hopital Avicenne - Bobigny
Connecticut
- Cancer Center of Central Connecticut - Southington
Florida
- Cancer and Blood Disease Center - Lecanto
Indiana
- Indiana University Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2009-10-19 |
| Est. Completion | 2017-09-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00963105
The ClinicalTrials.gov registry entry for NCT00963105 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which lenalidomide is the first listed.
NCT00963105 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00963105 about?
NCT00963105 is a clinical study titled "Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia". The purpose of this study is to determine the safety and effectiveness of different dose regimens of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
What is the current status of trial NCT00963105?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2009-10-19. Estimated completion is 2017-09-05.
What conditions does trial NCT00963105 study?
This clinical trial studies the following conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia.
What interventions are being tested in trial NCT00963105?
The interventions under investigation include: lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00963105?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00963105 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.